Positron emission tomography-computed tomography in paraneoplastic neurologic disorders: Systematic analysis and review

Archives of Neurology

Volumn 67, Issue 3, 2010, Pages 322-329

  McKeon, Andrew ^a   Apiwattanakul, Metha ^a   Lachance, Daniel H ^a   Lennon, Vanda A ^a,b   Mandrekar, Jayawant N ^a   Boeve, Bradley F ^a   Mullan, Brian ^a   Mokri, Bahram ^a   Britton, Jeffrey W ^a   Drubach, Daniel A ^a   Pittock, Sean J ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY;

ADENOCARCINOMA; ADULT; AGED; BREAST ADENOCARCINOMA; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; COLON ADENOCARCINOMA; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; GRANULOMA; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; MEDICAL RECORD REVIEW; METASTASIS; ONCOCYTOMA; PARANEOPLASTIC SYNDROME; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RETROSPECTIVE STUDY; REVIEW; SMALL CELL CARCINOMA; SQUAMOUS CELL CARCINOMA; THYROID ADENOMA; THYROID PAPILLARY CARCINOMA; TONSIL CARCINOMA; WHOLE BODY CT; WHOLE BODY PET;

ADULT; AGED; AGED, 80 AND OVER; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; NEOPLASMS; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; WHOLE BODY IMAGING;

EID: 77749332055     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2009.336     Document Type: Review

References (40)

1. Voltz RD, Posner JB, Dalmau J, Graus F. Paraneoplastic encephalomyelitis: an update of the effects of the anti-Hu immune response on the nervous system and tumour. J Neurol Neurosurg Psychiatry. 1997;63(2):133-136.
2. Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol. 2004;56(5):715-719.
3. Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, Lennon VA. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol. 2001;49(2):146-154.
4. Dalmau J, Furneaux HM, Gralla RJ, Kris MG, Posner JB. Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer: a quantitative western blot analysis. Ann Neurol. 1990;27(5):544-552.
5. Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology. 1998;50(3):652-657.
6. Sabater L, Titulaer M, Saiz A, Verschuuren J, Güre AO, Graus F. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology. 2008;70(12):924-928.
7. Furneaux HM, Rosenblum MK, Dalmau J, et al. Selective expression of Purkinjecell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. N Engl J Med. 1990;322(26):1844-1851.
8. Vernino S, Lennon VA. New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity. Ann Neurol. 2000;47(3):297-305.
9. De Camilli P, Thomas A, Cofiell R, et al. The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of Stiff-Man syndrome with breast cancer. J Exp Med. 1993;178(6):2219-2223.
10. Pittock SJ, Lucchinetti CF, Parisi JE, et al. Amphiphysin autoimmunity: paraneo-plastic accompaniments. Ann Neurol. 2005;58(1):96-107.
11. Luque FA, Furneaux HM, Ferziger R, et al. Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol. 1991;29(3):241-251.
12. Chan KH, Vernino S, Lennon VA. ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity. Ann Neurol. 2001;50(3):301-311.
13. Trotter JL, Hendin BA, Osterland CK. Cerebellar degeneration with Hodgkin disease: an immunological study. Arch Neurol. 1976;33(9):660-661.
14. Cooney CS, Khouri NF, Tsangaris TN. The role of breast MRI in the management of patients with breast disease. Adv Surg. 2008;42:299-312.
15. Kwok H, Bissett IP, Hill GL. Preoperative staging of rectal cancer. Int J Colorectal Dis. 2000;15(1):9-20.
16. Sadohara J, Fujimoto K, Muller NL, et al. Thymic epithelial tumors: comparison of CT and MR imaging findings of low-risk thymomas, high-risk thymomas, and thymic carcinomas. Eur J Radiol. 2006;60(1):70-79.
17. Bomanji JB, Costa DC, Ell PJ. Clinical role of positron emission tomography in oncology. Lancet Oncol. 2001;2(3):157-164.
18. Younes-Mhenni S, Janier MF, Cinotti L, et al. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain. 2004;127 (pt 10):2331-2338.
19. Linke R, Schroeder M, Helmberger T, Voltz R. Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology. 2004; 63(2):282-286.
20. Hadjivassiliou M, Alder SJ, Van Beek EJ, et al. PET scan in clinically suspected paraneoplastic neurological syndromes: a 6-year prospective study in a regional neuroscience unit. Acta Neurol Scand. 2009;119(3):186-193.
21. Rees JH, Hain SF, Johnson MR, et al. The role of [18F]fluoro-2- deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain. 2001;124(pt 11):2223-2231.
22. Bar-Shalom R, Yefremov N, Guralnik L, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med. 2003;44(8):1200-1209.
23. Tsukamoto E, Ochi S. PET/CT today: system and its impact on cancer diagnosis. Ann Nucl Med. 2006;20(4):255-267.
24. Ances BM, Vitaliani R, Taylor RA, et al. Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain. 2005;128 (pt 8):1764-1777.
25. Tan KM, Lennon VA, Klein CJ, Boeve BF, Pittock SJ. Clinical spectrum of voltagegated potassium channel autoimmunity. Neurology. 2008;70(20):1883-1890.
26. McKeon A, Lennon VA, Lachance DH, Fealey RD, Pittock SJ. Ganglionic acetylcholine receptor autoantibody: oncological, neurological, and serological accompaniments. Arch Neurol. 2009;66(6):735-741.
27. Veronesi G, Bellomi M, Veronesi U, et al. Role of positron emission tomography scanning in the management of lung nodules detected at baseline computed tomography screening. Ann Thorac Surg. 2007;84(3):959-966.
28. Aygun C. Small cell carcinoma of the prostate: a case report and review of the literature. Md Med J. 1997;46(7):353-356.
29. Quon A, Fischbein NJ, McDougall IR, et al. Clinical role of 18F-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma. J Nucl Med. 2007;48(suppl 1):58S-67S.
30. Bar-Shalom R, Kagna O, Israel O, Guralnik L. Noninvasive diagnosis of solitary pulmonary lesions in cancer patients based on 2-fluoro-2-deoxy-D- glucose avidity on positron emission tomography/computed tomography. Cancer. 2008; 113(11):3213-3221.
31. Rostom AY, Powe J, Kandil A, et al. Positron emission tomography in breast cancer: a clinicopathological correlation of results. Br J Radiol. 1999;72(863): 1064-1068.
32. Chin BB, Chang PP. Gastrointestinal malignancies evaluated with (18)F-fluoro-2-deoxyglucose positron emission tomography. Best Pract Res Clin Gastroenterol. 2006;20(1):3-21.
33. Gutman F, Alberini JL, Wartski M, et al. Incidental colonic focal lesions detected by FDG PET/CT. AJR Am J Roentgenol. 2005;185(2):495-500.
34. Lai CH, Yen TC, Chang TC. Positron emission tomography imaging for gynecologic malignancy. Curr Opin Obstet Gynecol. 2007;19(1):37-41.
35. Schick V, Franzius C, Beyna T, et al. Diagnostic impact of 18F-FDG PET-CT evaluating solid pancreatic lesions versus endosonography, endoscopic retrograde cholangio-pancreatography with intraductal ultrasonography and abdominal ultrasound. Eur J Nucl Med Mol Imaging. 2008;35(10):1775-1785.
36. Fuchsjäger M, Shukla-Dave A, Akin O, Barentsz J, Hricak H. Prostate cancer imaging. Acta Radiol. 2008;49(1):107-120.
37. Basu S, Rubello D. PET imaging in the management of tumors of testis and ovary: current thinking and future directions. Minerva Endocrinol. 2008;33(3):229-256.
38. Bouchelouche K, Oehr P. Recent developments in urologic oncology: positron emission tomography molecular imaging. Curr Opin Oncol. 2008;20(3):321-326.
39. Park JW, Kim JH, Kim SK, et al. A prospective evaluation of 18F-FDG and 11Cacetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med. 2008;49(12):1912-1921.
40. Lim JW, Tang CL, Keng GH. False positive F-18 fluorodeoxyglucose combined PET/CT scans from suture granuloma and chronic inflammation: report of two cases and review of literature. Ann Acad Med Singapore. 2005;34(7):457-460.